Tirzepatide does, and it overshoots in some people. Pooled across 32 randomized trials and 47,332 participants, it cut hypertension-related adverse events to a risk ratio of 0.40. It raised hypotension-related events to 2.45, rising to 2.58 at higher doses. Semaglutide was neutral on both.
The outcome here is recorded adverse events, not measured blood pressure. A separate post hoc analysis measured it. It counted how many people hit three targets at once. A weight threshold, a systolic fall of at least 5 mmHg, and non-HDL cholesterol under 130 mg/dL. At the 15% weight threshold, 22% to 34% of treated participants managed all three, against 1% to 3% on placebo [2]. Most treated participants did not hit all three, which is what a triple endpoint looks like from the inside.
Most comparisons between these two molecules end up being about how much weight comes off. Here is one that is not, and it produces a genuine trade rather than a winner — which is rarer than the premium question usually allows.
What was counted
Thirty-two randomized controlled trials, 47,332 participants, searched across six sources to September 2025. [1] The outcomes were hypertension-related and hypotension-related treatment-emergent adverse events — things recorded as having happened to participants, not readings taken from a cuff. That distinction matters and the paper’s own title blurs it: no millimeters of mercury appear in these results.
The trade
Tirzepatide was associated with a lower risk of hypertension-related events, RR 0.40, 95% CI 0.26 to 0.60, p<0.001. That is a large reduction and it is the kind of finding that gets quoted alone.
It was also associated with more hypotension-related events, RR 2.45, 95% CI 1.35 to 4.45, p=0.003. At higher doses that rose to RR 2.58, 95% CI 1.38 to 4.81. Both halves are the same drug doing the same thing: lowering blood pressure. In someone with hypertension that is a benefit. In someone whose pressure is already low, or who is on medication for high pressure, it is a hazard.
Semaglutide did neither
For semaglutide the hypertension-related risk ratio was 0.81, 95% CI 0.57 to 1.15, and the hypotension-related risk ratio 1.39, 95% CI 0.81 to 2.36. Both intervals include no effect, so on this outcome semaglutide looks neutral in both directions.
That is worth internalizing about this class. The molecules are not interchangeable, and a class-level claim can hide a split that matters more than the average.
What it is worth paying for
Across the 370 sellers here publishing both molecules by injection, read September 2026, tirzepatide runs a median of $61 more a month. On this outcome the difference buys a real reduction in one adverse event and a real increase in another. Which matters depends on your own blood pressure. No product page knows that about you. The current spread is in the price check.
Side-effect profiles are also not a single axis running from gentle to harsh, which is how they get sold. paying more for a gentler experience assumes a ranking that this result does not support.
What the design cannot tell you
How big any of this is in absolute terms. Risk ratios describe proportional change and the abstract gives no event rates. So a reader cannot tell whether a 2.45-fold increase means a rare thing became less rare, or a common thing became commoner. Without those numbers the practical size of the trade is unknown.
And adverse-event capture varies between trials — what one study records as a hypotension-related event another may not record at all. Pooling 32 trials averages over that inconsistency rather than resolving it.